DirectorsTalk Interviews

Author: Giles Arbor

DirectorsTalk Interviews focus on financial markets and investment opportunities. The site features interviews with company directors, market analysts, and experts, offering insights into companies' performance, industry trends, and market updates. The content includes Q&A sessions, market commentary, and discussions about business developments, often highlighting the viewpoints of executives from publicly traded companies.
Be a guest on this podcast

Language: en-gb

Genres: Business, Investing

Contact email: Get it

Feed URL: Get it

iTunes ID: Get it

Get all podcast data

Listen Now...

EDX Medical Group: Sir Chris Evans on the Diagnostics Shift That Could Redefine Early Cancer Detection
Tuesday, 12 May, 2026

Cancer diagnostics are moving beyond broad screening and into precision-led detection, and Sir Chris Evans believes EDX Medical Group (LON:EDX) is positioned at the centre of that transition. In this interview, the founder and Chief Scientific Officer explains why the company is focusing on high-accuracy, clinically validated testing, how partnerships are accelerating commercial traction, and where he sees the biggest gaps in modern healthcare diagnostics. The conversation also touches on scaling revenues, expanding the product pipeline, and why earlier intervention could dramatically change patient outcomes and healthcare costs.Key Moments00:16 – EDX Medical lands on AIM01:05 – Taking ultra-accurate tests into the home02:14 – Sir Chris Evans’ biotech track record03:21 – The $10bn Verona Pharma win04:18 – The big names backing EDX06:05 – Scotland’s prostate testing push07:16 – 25,000 men, major data set08:23 – Finding cancer before symptoms09:15 – Predicting what MRI will show11:04 – Bowel cancer test launch plans12:18 – Ovarian, lung and breast next13:25 – From R&D to commercial sales14:10 – Why home diagnostics matter14:52 – Evans’ next big biotech betAbout EDX Medical GroupEDX Medical Group develops innovative digital diagnostic products and services focused on early disease detection, personalised treatment support, and improving clinical outcomes, with a particular emphasis on cancer and cardiovascular disease diagnostics.